Glyceollin, a novel regulator of mTOR/p70S6 in estrogen receptor positive breast cancer.

The Journal of Steroid Biochemistry and Molecular Biology
Melyssa R BrattonMatthew E Burow

Abstract

An estimated 70% of breast cancer tumors utilize estrogen receptor (ER) signaling to maintain tumorigenesis and targeting of the estrogen receptor is a common method of treatment for these tumor types. However, ER-positive (+) breast cancers often acquire drug resistant or altered ER activity in response to anti-estrogens. Here we demonstrate glyceollin, an activated soy compound, has anti-estrogen effects in breast cancers. We demonstrate through estrogen response element luciferase and phosphorylation-ER mutants that the effects of glyceollin arise from mechanisms distinct from conventional endocrine therapies. We show that glyceollin suppresses estrogen response element activity; however, it does not affect ER-alpha (α) phosphorylation levels. Additionally we show that glyceollin suppresses the phosphorylation of proteins known to crosstalk with ER signaling, specifically we demonstrate an inhibition of ribosomal protein S6 kinase, 70 kDa (p70S6) phosphorylation following glyceollin treatment. Our data suggests a mechanism for glyceollin inhibition of ERα through the induced suppression of p70S6 and demonstrates novel mechanisms for ER inhibition.

References

Oct 16, 1991·Journal of the National Cancer Institute·B S Katzenellenbogen
Jan 1, 1994·Annual Review of Biochemistry·M J Tsai, B W O'Malley
Feb 1, 1996·Biology of Reproduction·B S Katzenellenbogen
Mar 30, 2002·Science·Yongfeng Shang, Myles Brown
Jul 26, 2002·Molecular and Cellular Biology·Heehyoung Lee, Wenlong Bai
Aug 29, 2003·The Journal of Steroid Biochemistry and Molecular Biology·Paolo G V Martini, Benita S Katzenellenbogen
Jan 27, 2004·The Journal of Pharmacology and Experimental Therapeutics·Amanda P StruckhoffBarbara S Beckman
Dec 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Virgilo A SalvoMatthew E Burow
Aug 30, 2008·The Journal of Clinical Investigation·Arkaitz CarracedoPier Paolo Pandolfi
Jun 30, 2009·Clinical Breast Cancer·Susan J CleatorCarlo Palmieri
Oct 3, 2009·The Journal of Pharmacology and Experimental Therapeutics·M Carla ZimmermannMatthew E Burow
Dec 1, 2010·Clinical Breast Cancer·Amna SheriStephen Johnston

❮ Previous
Next ❯

Citations

May 9, 2015·Functional & Integrative Genomics·Sanaya F BamjiCynthia Corbitt
Apr 16, 2019·Plant Signaling & Behavior·Md Asraful Jahan, Nik Kovinich
Feb 23, 2020·International Journal of Molecular Sciences·Thu Ha PhamFarzad Pakdel
Sep 12, 2020·Recent Patents on Anti-cancer Drug Discovery·Arunaksharan Narayanankutty

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer -Omics

A variety of different high-throughput technologies can be used to identify the complete catalog of changes that characterize the molecular profile of cohorts of tumor samples. Discover the latest insights gained from cancer 'omics' in this feed.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

© 2021 Meta ULC. All rights reserved